Novo Nordisk will pay up to $1.3 billion to buy a small molecule currently in Phase III for uncontrolled hypertension and advanced chronic kidney disease as it looks to go up against Bayer’s Kerendia.
The Danish behemoth, valued higher than most other European companies thanks to a surge in demand for its diabetes and weight loss drugs, will acquire the treatment candidate from Singapore biotech KBP Biosciences, the companies said Monday morning.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.